Sustained Remission of a Primary Nodal Merkel Cell Carcinoma in an HIV-Positive Patient

Pierluigi Brugnaro \( ^a \) Erika Morelli \( ^a \) Marta Fiscon \( ^a \) Francesca Ebo \( ^a \) Giorgio Rosini \( ^a \) Fabio Belussi \( ^a \) Franklyn Eseme \( ^a \) Carlo A. Mione \( ^b \) Pietro M. Donisi \( ^c \) Enzo Raise \( ^a \)

\( ^a \)Infectious Diseases Division, \( ^b \)Oncology and Radiotherapy Service, \( ^c \)Pathology Department, ‘SS. Giovanni e Paolo’ Hospital, Venice, Italy

Case Report · Kasuistik

Sustained Remission of a Primary Nodal Merkel Cell Carcinoma in an HIV-Positive Patient

Pierluigi Brugnaro \( ^a \) Erika Morelli \( ^a \) Marta Fiscon \( ^a \) Francesca Ebo \( ^a \) Giorgio Rosini \( ^a \) Fabio Belussi \( ^a \) Franklyn Eseme \( ^a \) Carlo A. Mione \( ^b \) Pietro M. Donisi \( ^c \) Enzo Raise \( ^a \)

\( ^a \)Infectious Diseases Division, \( ^b \)Oncology and Radiotherapy Service, \( ^c \)Pathology Department, ‘SS. Giovanni e Paolo’ Hospital, Venice, Italy

Keywords
Chemotherapy · HIV infection · Merkel cell carcinoma · Radiotherapy

Introduction

Merkel cell carcinoma (MCC) is an uncommon, highly malignant skin cancer of neuroendocrine origin that occurs more often in sun-exposed areas of the body, such as the head and neck, and generally affects elderly patients. The tumor is clinically aggressive, showing a high propensity for local, regional, and distant spread. An increased incidence of MCC has been reported in association with other malignancies, immunosuppressive treatments following organ transplantation, and human immunodeficiency virus (HIV) infection.

Case Report

The patient, now aged 66 years, was found to be HIV positive in 1984 after an occupational accident in a hospital where he was working as a nurse. 2 years after the initial diagnosis he developed pleural tuberculosis, but he had no further hospital admissions related to acquired immunodeficiency syndrome (AIDS)-defining diseases. He was treated with sequential and dual nucleoside therapy until 1996, when he started highly active antiretroviral therapy (HAART), and his current medications were unboosted saquinavir, lamivudine and stavudine. He also had hypertension, hyperlipidemia, and lipoatrophy. The patient was also treated from 2004 to 2007 with recombinant interleukin-2 (IL-2) as he had been enrolled in an international multicenter study [1]. In April 2008, the patient was admitted to our department because of a painful left inguinal mass that had grown slowly during the previous 3 months. His CD4 T lymphocytes were 479/\( \mu \)l and plasma HIV-RNA was consistently below 40 copies/ml. 2 years before this evaluation, a squamous cell carcinoma had been removed from the skin of the penis. A biopsy of the inguinal nodule revealed a dense growth of malignant cells infiltrating the lymph nodes and subcutaneous tissues, with areas of necrosis and fluid collections. A positron emission tomography (PET) scan displayed a markedly increased activity at this nodal location, and a computed tomography (CT) scan of the chest and abdomen did not show any pathological lesions at other sites. Wide surgical resection of the tumor with inguinal lymph node excision was performed, and the pathological examination with immunohistochemical studies (positive cytokeratin 20, neuron-specific enolase and synaptophysin staining; negative cytokeratin 7 and thyroid-transcription factor-1 staining) led to a confirmed diagnosis of MCC stage III, according to the system proposed by Allen et al. [2] (figs. 1–4). The patient underwent postoperative radiotherapy of the inguinal nodal disease for a total of 45 Gy administered over 25 treatment sessions. It was also decided to start adjuvant combination chemotherapy with carboplatin and etoposide, which the patient received for 6 rounds over a 3-month period. The treatment was well tolerated by the patient and HAART was not discontinued. At the end of the radiation and chemotherapy cycles, the absolute count of the patient’s CD4 T cells fell to 170/\( \mu \)l but the viral load still remained undetectable, and neither opportunistic diseases nor severe drug-related side effects were experienced. The patient is now 24 months since the initial diagnosis of MCC and 18 months since completion of oncological treatment, with no clinical evidence of disease relapse, and a total body PET-CT scan did not demonstrate any pathological findings.

Discussion

MCC is an unusual cutaneous malignancy that is seen primarily in the older white population. Based on data from the U.S. Surveillance, Epidemiology and End Results (SEER) program, the incidence rate of MCC has tripled from 0.15 per 100,000 in 1986 to 0.44 per 100,000 in 2001 [3]. Many patients with MCC have had a history of other synchronous or metachronous sun-associated skin cancers, implying that excessive sun exposure is a pathogenetic factor for developing MCC [4]. This malignancy has also been observed as a second primary cancer among patients with multiple myeloma, chronic lymphocytic leukemia, and non-Hodgkin’s lymphoma [5]. Even though MCC is not considered an AIDS-defining disease like Kaposi’s sarcoma, non-Hodgkin’s lymphoma, and cervical carcinoma, the relative risk of MCC has been shown to be 13.4 in HIV-positive patients compared with the general population [6]. Recently, a small novel polyomavirus,
Merkel Cell Carcinoma in an HIV-Positive Patient

provisionally named Merkel cell polyomavirus (MCPyV), was found in MCC tissue, suggesting a role of this virus in the pathogenesis of the carcinoma [7]. The prevalence of MCPyV DNA in MCCs may vary in different populations [8]. We did not perform the MCPyV DNA analysis in the tissue sample. This is a limitation of our work. Reviewing our case and the 11 patients with MCC and HIV infection reported in the literature (table 1) [9–19], the mean age was 50 years (range, 25–66) whereas the mean age among non-HIV-infected patients with MCC is 69 years. The mean time from HIV diagnosis to the onset of MCC was 12 years (range, 3–25 years). In 4 out of 9 patients, the CD4 T lymphocyte count was below 200 cells/μl (36%), and only 1 patient was reported to have had an opportunistic disease before MCC diagnosis. Involvement of regional lymph nodes (stage III) was present in 6 out of 12 patients (50%). Our case is remarkable since no primary lesion was found. A similar presentation was previously described by Samarendra et al. [12]. All patients reported in the literature underwent surgery; 9 out of 12 patients (75%) received radiation therapy. Although recent studies have not demonstrated a significant survival benefit with the addition of chemotherapy [20], and despite the risk of administering systemic chemotherapy to immunosuppressed patients such as HIV-positive individuals, the majority of patients also received adjuvant chemotherapy (8 out of 12 patients, 67%). The association of etoposide and cisplatin (or carboplatin) was the most commonly used chemotherapy regimen. The good Karnofsky performance status of our patient and the stable control of HIV infection obtained with HAART encouraged us to administer adjuvant chemotherapy, which was well tolerated. It is noteworthy that another HIV-positive patient who developed MCC was subsequently treated with IL-2 combined with HAART and the cancer regressed [13]. In our case, administration of IL-2 preceded the MCC onset. At

Fig. 1. Biopsy specimen of the inguinal lymph node: hematoxylin/eosin staining (magnification ×40). The cells appear with a scanty cytoplasm and vesicular nuclei with a salt-and-pepper-like chromatin. Mitotic figures are also present.

Fig. 2. Biopsy specimen of the inguinal lymph node: Immunohistochemical staining for cytokeratin 20 on the tumoral cells shows a dot-like pattern (magnification ×20).

Fig. 3. Biopsy specimen of the inguinal lymph node: Immunohistochemical staining for neuron-specific enolase was positive on tumoral cells (magnification ×20).

Fig. 4. Biopsy specimen of the inguinal lymph node: Immunohistochemical staining for thyroid-transcription factor-1 was negative on tumoral cells (magnification ×20).
present, the role of recombinant IL-2 in combination with HAART for the treatment of HIV infection is still questionable since a randomized multicenter study recently failed to demonstrate that IL-2 in combination with antiretroviral therapy reduces the rate of opportunistic diseases or death [1]. At the time of last follow-up, 6 patients with MCC (50%) were alive and the mean time of follow-up for these patients was 25 months (range, 9–42 months). MCC is a rare but very aggressive tumor that has been reported with a higher incidence in HIV-positive individuals than in the general population. Reviewing the management of the HIV-positive patients with MCC, only 2 patients with local disease underwent surgical intervention alone. Immunosuppression or the risk of toxicity and HAART discontinuation did not discourage the majority of authors from administering adjuvant radiation and chemotherapy. Such interventions should be considered because of the high risk of locoregional and distant relapse of this cancer. Until data from multi-institutional trials are collected, the role of adjuvant radiation therapy and chemotherapy for MCC will continue to be debated.

Disclosure Statement
The authors state no financial or personal relationships with other persons or organizations that inappropriately influenced this work.

References

Table 1. Clinical findings, treatment and outcome of 12 cases of HIV-associated MCC

<table>
<thead>
<tr>
<th>Reference number</th>
<th>Sex</th>
<th>Age at MCC diagnosis, years</th>
<th>MCC location</th>
<th>Time from HIV infection to MCC, years</th>
<th>CD4+ count, cells/μl</th>
<th>Previous opportunistic diseases</th>
<th>MCC stage</th>
<th>Treatment</th>
<th>Survival, months</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>f</td>
<td>36</td>
<td>ear lobe</td>
<td>14</td>
<td>63</td>
<td>none</td>
<td>II</td>
<td>surgery</td>
<td>&gt;9</td>
</tr>
<tr>
<td>10</td>
<td>f</td>
<td>25</td>
<td>face</td>
<td>unknown</td>
<td>332</td>
<td>unknown</td>
<td>III</td>
<td>surgery, RT, CT</td>
<td>11</td>
</tr>
<tr>
<td>11</td>
<td>m</td>
<td>57</td>
<td>finger</td>
<td>14</td>
<td>357–573</td>
<td>none</td>
<td>I</td>
<td>surgery, RT, CT</td>
<td>&gt;40</td>
</tr>
<tr>
<td>12</td>
<td>m</td>
<td>40</td>
<td>inguinal node</td>
<td>3</td>
<td>160</td>
<td>none</td>
<td>II</td>
<td>surgery</td>
<td>&gt;42</td>
</tr>
<tr>
<td>13</td>
<td>m</td>
<td>52</td>
<td>buttock</td>
<td>10</td>
<td>267</td>
<td>III</td>
<td>surgery, RT</td>
<td>&gt;11</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>m</td>
<td>47</td>
<td>buttock</td>
<td>unknown</td>
<td>625</td>
<td>III</td>
<td>surgery, RT</td>
<td>&gt;23</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>m</td>
<td>48</td>
<td>scalp</td>
<td>12</td>
<td>within normal range</td>
<td>unknown</td>
<td>III</td>
<td>surgery, RT</td>
<td>12</td>
</tr>
<tr>
<td>16</td>
<td>m</td>
<td>60</td>
<td>nasal bridge</td>
<td>unknown</td>
<td>unknown</td>
<td>unknown</td>
<td>I</td>
<td>surgery, RT</td>
<td>21</td>
</tr>
<tr>
<td>17</td>
<td>m</td>
<td>51</td>
<td>gluteus</td>
<td>6</td>
<td>122</td>
<td>unknown</td>
<td>II</td>
<td>surgery, RT, CT</td>
<td>9</td>
</tr>
<tr>
<td>18</td>
<td>m</td>
<td>54</td>
<td>arm</td>
<td>82</td>
<td>unknown</td>
<td>II</td>
<td>surgery, CT</td>
<td>25</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>m</td>
<td>63</td>
<td>head</td>
<td>12</td>
<td>232</td>
<td>Pneumocytis pneumonia</td>
<td>III</td>
<td>surgery, RT, CT</td>
<td>15</td>
</tr>
<tr>
<td>Present case</td>
<td>m</td>
<td>66</td>
<td>inguinal node</td>
<td>25</td>
<td>479</td>
<td>none</td>
<td>III</td>
<td>surgery, RT, CT</td>
<td>&gt;24</td>
</tr>
</tbody>
</table>

CT = Chemotherapy; RT = radiotherapy.